Sialomucin core protein 24 (CD164) (CD164)

Sialomucin core protein 24 (CD164) is a type I transmembrane sialomucin that functions as a key regulator of cell adhesion and migration (UniProt Q04900) [1]. It is predominantly expressed on hematopoietic stem and progenitor cells, where it modulates the CXCR4/CXCL12 signaling pathway to control cell homing and hematopoiesis (NCBI Gene 8763) [2]. In the context of oncology, CD164 is frequently overexpressed in various malignancies, including glioblastoma and colon cancer, promoting tumor cell proliferation, invasion, and metastasis through the induction of epithelial-mesenchymal transition (PMID: 28656234) [4]. Furthermore, CD164 is essential for the structural integrity of the inner ear, and specific mutations in its gene lead to progressive nonsyndromic hearing loss (PMID: 29706351) [3]. Therapeutic strategies targeting CD164 are currently in the preclinical stage, focusing on the use of monoclonal antibodies to block protein function or siRNA to degrade CD164 mRNA, thereby reducing its expression in cancerous tissues (PMID: 31110218) [5].

Other names

MGC-24EndolynMulti-glycosylated core protein 24CD164 antigen

mRNA degradation via RNA interference (siRNA) or protein neutralization via monoclonal antibodies to inhibit cell adhesion and signaling pathways.